Antifungal Efficacy of Amphotericin B in Candida Albicans Endocarditis Therapy: Systematic Review
Abstract Introduction: Although it is the most common agent among the fungal causes of endocarditis, Candida albicans endocarditis is rare. Objective: To evaluate the efficacy of amphotericin B in the treatment of C. albicans endocarditis beyond a systematic review. Data search: Articles in English, Spanish and Portuguese, conducted in the following databases: MEDLINE, LILACS, IBECS and SciELO, in humans and published in the last 25 years. Study selection: Observational studies, clinical trials, and case series providing data on the amphotericin B use in patients with a C. albicans endocarditis diagnosis without age limitations. Data synthesis: From the initial search (n=79), 25 articles were fully evaluated, of which 19 were excluded for meeting one or more exclusion criteria, remaining five articles (two observational studies and three case series). Patients using amphotericin B demonstrated improvement in survival rates, and its main use was in association with the surgical method as well as with caspofungin association. Conclusion: Literature lacks evidence to conclude about efficacy and safety of amphotericin B in the treatment of fungal endocarditis. Randomized clinical trials are necessary to provide better evidence on the subject.
Main Authors: | , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Cirurgia Cardiovascular
2020
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382020000500026 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0102-76382020000500026 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0102-763820200005000262020-10-20Antifungal Efficacy of Amphotericin B in Candida Albicans Endocarditis Therapy: Systematic ReviewBezerra,Lucas SoaresSilva,Janielli Assis daSantos-Veloso,Marcelo Antônio OliveiraLima,Sandro Gonçalves deChaves-Markman,Ândrea VirgíniaJucá,Moacir Batista Amphotericin B Antifungal Agents Candida Albicans Endocarditis, Mycoses, Survival Rate Abstract Introduction: Although it is the most common agent among the fungal causes of endocarditis, Candida albicans endocarditis is rare. Objective: To evaluate the efficacy of amphotericin B in the treatment of C. albicans endocarditis beyond a systematic review. Data search: Articles in English, Spanish and Portuguese, conducted in the following databases: MEDLINE, LILACS, IBECS and SciELO, in humans and published in the last 25 years. Study selection: Observational studies, clinical trials, and case series providing data on the amphotericin B use in patients with a C. albicans endocarditis diagnosis without age limitations. Data synthesis: From the initial search (n=79), 25 articles were fully evaluated, of which 19 were excluded for meeting one or more exclusion criteria, remaining five articles (two observational studies and three case series). Patients using amphotericin B demonstrated improvement in survival rates, and its main use was in association with the surgical method as well as with caspofungin association. Conclusion: Literature lacks evidence to conclude about efficacy and safety of amphotericin B in the treatment of fungal endocarditis. Randomized clinical trials are necessary to provide better evidence on the subject.info:eu-repo/semantics/openAccessSociedade Brasileira de Cirurgia CardiovascularBrazilian Journal of Cardiovascular Surgery v.35 n.5 20202020-10-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382020000500026en10.21470/1678-9741-2019-0159 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Bezerra,Lucas Soares Silva,Janielli Assis da Santos-Veloso,Marcelo Antônio Oliveira Lima,Sandro Gonçalves de Chaves-Markman,Ândrea Virgínia Jucá,Moacir Batista |
spellingShingle |
Bezerra,Lucas Soares Silva,Janielli Assis da Santos-Veloso,Marcelo Antônio Oliveira Lima,Sandro Gonçalves de Chaves-Markman,Ândrea Virgínia Jucá,Moacir Batista Antifungal Efficacy of Amphotericin B in Candida Albicans Endocarditis Therapy: Systematic Review |
author_facet |
Bezerra,Lucas Soares Silva,Janielli Assis da Santos-Veloso,Marcelo Antônio Oliveira Lima,Sandro Gonçalves de Chaves-Markman,Ândrea Virgínia Jucá,Moacir Batista |
author_sort |
Bezerra,Lucas Soares |
title |
Antifungal Efficacy of Amphotericin B in Candida Albicans Endocarditis Therapy: Systematic Review |
title_short |
Antifungal Efficacy of Amphotericin B in Candida Albicans Endocarditis Therapy: Systematic Review |
title_full |
Antifungal Efficacy of Amphotericin B in Candida Albicans Endocarditis Therapy: Systematic Review |
title_fullStr |
Antifungal Efficacy of Amphotericin B in Candida Albicans Endocarditis Therapy: Systematic Review |
title_full_unstemmed |
Antifungal Efficacy of Amphotericin B in Candida Albicans Endocarditis Therapy: Systematic Review |
title_sort |
antifungal efficacy of amphotericin b in candida albicans endocarditis therapy: systematic review |
description |
Abstract Introduction: Although it is the most common agent among the fungal causes of endocarditis, Candida albicans endocarditis is rare. Objective: To evaluate the efficacy of amphotericin B in the treatment of C. albicans endocarditis beyond a systematic review. Data search: Articles in English, Spanish and Portuguese, conducted in the following databases: MEDLINE, LILACS, IBECS and SciELO, in humans and published in the last 25 years. Study selection: Observational studies, clinical trials, and case series providing data on the amphotericin B use in patients with a C. albicans endocarditis diagnosis without age limitations. Data synthesis: From the initial search (n=79), 25 articles were fully evaluated, of which 19 were excluded for meeting one or more exclusion criteria, remaining five articles (two observational studies and three case series). Patients using amphotericin B demonstrated improvement in survival rates, and its main use was in association with the surgical method as well as with caspofungin association. Conclusion: Literature lacks evidence to conclude about efficacy and safety of amphotericin B in the treatment of fungal endocarditis. Randomized clinical trials are necessary to provide better evidence on the subject. |
publisher |
Sociedade Brasileira de Cirurgia Cardiovascular |
publishDate |
2020 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382020000500026 |
work_keys_str_mv |
AT bezerralucassoares antifungalefficacyofamphotericinbincandidaalbicansendocarditistherapysystematicreview AT silvajanielliassisda antifungalefficacyofamphotericinbincandidaalbicansendocarditistherapysystematicreview AT santosvelosomarceloantoniooliveira antifungalefficacyofamphotericinbincandidaalbicansendocarditistherapysystematicreview AT limasandrogoncalvesde antifungalefficacyofamphotericinbincandidaalbicansendocarditistherapysystematicreview AT chavesmarkmanandreavirginia antifungalefficacyofamphotericinbincandidaalbicansendocarditistherapysystematicreview AT jucamoacirbatista antifungalefficacyofamphotericinbincandidaalbicansendocarditistherapysystematicreview |
_version_ |
1756429598218780672 |